SEC Comment Letter 0000000000-23-003057 to Virax Biolabs Group Ltd (VRAX) (CIK 0001885827) (VRAX)
Virax Biolabs Group Ltd (VRAX) (CIK 0001885827)
Date: March 28, 2023 · CIK: 0001885827 · Accession: 0000000000-23-003057
AI Filing Summary & Sentiment
File numbers found in text: 333-270734
Letter
United States securities and exchange commission logo March 28, 2023 James Foster Chief Executive Officer Virax Biolabs Group Ltd 20 North Audley Street London, W1K 6LX United Kingdom Re:Virax Biolabs Group Ltd Registration Statement on Form F-1 Filed March 22, 2023 File No. 333-270734 Dear James Foster: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Lawrence Venick
Show Raw Text
United States securities and exchange commission logo
March 28, 2023
James Foster
Chief Executive Officer
Virax Biolabs Group Ltd
20 North Audley Street
London, W1K 6LX
United Kingdom
Re:Virax Biolabs Group Ltd
Registration Statement on Form F-1
Filed March 22, 2023
File No. 333-270734
Dear James Foster:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Lawrence Venick